 We're very excited that the drug has been approved for use in surgery of ovarian cancer. It's going to be technically called cytolux on the market. It's kind of a combination of two different Latin words, cyt, cyt, meaning the basic word for cell and lux, the word for light, so lighted cell. For years, we had been designing tumor targeting ligands that would home in very specifically two cancer cells and avoid uptake by healthy cells. Because we noticed the specificity for tumors and following discussions with actually a group of surgeons from the Netherlands, we learned that there was still a major problem experienced by surgeons in finding, locating, all of the malignant lesions during a surgery. In many cases, malignant lesions appear at least to the naked eye, no different from adjacent healthy tissues. The patient is injected before surgery with this tumor targeted fluorescent dye and during the preparation of the patient for the actual surgery, this dye circulates in the blood veins and blood vessels and localizes to the tumor tissue. And so you have within a couple of hours very good fluorescent dye accumulation in tumor tissue. And when you turn on the fluorescent lamp, then those lesions light up like bright stars against a black sky and it allows the surgeon to see exactly where these hidden disease tissues are located and then they can go in and remove them. Every 23 minutes in the United States, another woman is diagnosed with ovarian cancer and our very first molecule will be approved for treating ovarian cancer. In 2015, when I met with Dr. Tanya and he knew that something was going on, it was my first recurrence. It was stage three and it was very serious. He explained to me that I qualified for a clinical trial. The clinical trial was a fluorescent dye that I had injected prior to surgery going to the OR. He explained to me that it's a safe procedure and will infuse you prior to surgery. I have a special light that I will shine and we will look for other nodules that were not present on the CT scan. And lo and behold, he found the nodule and was delighted. Dr. Phil Lau was instrumental in setting up on target laboratories. In fact, he's our founder. Cytolux was developed in Dr. Lau's lab. Our relationship with Purdue University is instrumental to the future of on target laboratories. There's no doubt that that relationship has been a very positive one. I grew up in West Lafayette. I went to West Lafayette High School. My dad was a professor at Purdue. My mom was here. So when they offered me a job at Purdue, I accepted. It was basically coming back home. I'm a Purdue fan. I grew up going to all the Purdue basketball and football games and I, I bleed golden black. Dr. Lau's commitment to this technology has been unwavering his ability to champion that early on and drive that from the early research stage to the clinical stage. We would not be where we are today. I'm just glad that we're on this end of it to pull it across the finish line for him. I feel grateful for this opportunity. It's there are a lot of people that come on this planet and don't really have an opportunity to leave a footprint. And I think, you know, just often in many cases due to, you know, the good blessings and good luck, we've been able to find this opportunity and develop it and make it available to the general public. There's a great deal of satisfaction in knowing that you've done something that can help a lot of people.